Neurology® Podcast

1) Evaluation, diagnosis and management of facioscapulohumeral muscular dystrophy and 2) Topic of the month: Plenary sessions AAN Meeting April 2015. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Rabi Tawil about his paper on the evaluation, diagnosis and management of facioscapulohumeral muscular dystrophy. Dr. Sarah Wesley is reading our e-Pearl of the week about vertical nystagmus. In the next part of the podcast Dr. Alberto Espay interviews Dr. Helen Mayberg about her Robert Wartenberg Lecture at the AAN Meeting on the topic of what deep brain stimulation has taught us about the neurology of depression. The participants had nothing to disclose except Drs. Burns, Tawil, Wesley and Espay.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc.Dr. Tawil serves as an editorial board member of Journal of Neuromuscular Diseases; serves on the safety monitoring board of Novartis; receives royalties from the publication of the books Neuromuscular Disorders (Rabi N. Tawil & Shannon Venance, Editors) and Neurology in Practice Series; receives research support from the NIH and Spinal Muscular Atrophy Foundation.Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as an Associate Editor of Movement Disorders, Frontiers in Movement Disorders and Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; receives royalties for publications of books from Lippincott, Williams & Wilkins and from Cambridge University Press; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics, Teva Pharmaceutical Industries Ltd., Impax Pharmaceuticals, Merz, Pfizer Inc, Solstice Neurosciences, LLC, Eli Lilly and Company, US WorldMeds; is a consultant for Chelsea Therapeutics, Solvay Pharmaceuticals, Inc. (now Abbvie); serves on the speakers' bureaus of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology, Movement Disorders Society; receives research support from CleveMed/Great Lakes Neurotechnologies, Michael J. Fox Foundation and the NIH.

1) Paraneoplastic neurologic disorders in small cell lung carcinoma and 2) Topic of the month: Plenary sessions AAN Meeting April 2015. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Elliot Dimberg interviews Dr. Paul Gozzard about his paper on paraneoplastic neurologic disorders in small cell lung carcinoma. Dr. Sarah Wesley is reading our e-Pearl of the week about Balint Syndrome. In the next part of the podcast Dr. Alberto Espay interviews Dr. Lloyd Kasper about his Hot Topic Lecture at the AAN Meeting on the topic of digesting the gut microbiome: role in CNS demyelinating disease. The participants had nothing to disclose except Drs. Dimberg, Wesley and Espay.Dr. Dimberg serves as an editorial board member of Nerve and Muscle Junction Podcast.Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as an Associate Editor of Movement Disorders, Frontiers in Movement Disorders and Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; receives royalties for publications of books from Lippincott, Williams & Wilkins and from Cambridge University Press; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics, Teva Pharmaceutical Industries Ltd., Impax Pharmaceuticals, Merz, Pfizer Inc, Solstice Neurosciences, LLC, Eli Lilly and Company, US WorldMeds; is a consultant for Chelsea Therapeutics, Solvay Pharmaceuticals, Inc. (now Abbvie); serves on the speakers' bureaus of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology, Movement Disorders Society; receives research support from CleveMed/Great Lakes Neurotechnologies, Michael J. Fox Foundation and the NIH.

1) Early EEG contributing to multimodal outcome prediction of postanoxic coma and 2) Topic of the month: Plenary sessions AAN Meeting April 2015. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Schomer interviews Dr. Jeannette Hofmeijer about her paper on early EEG contributing to multimodal outcome prediction of postanoxic coma. Dr. Sarah Wesley is reading our e-Pearl of the week about Susac syndrome. In the next part of the podcast Dr. Alberto Espay interviews Dr. Daniel Lowenstein about his H. Houston Merritt Lecture at the AAN Meeting on the topic of advances in the treatments for epilepsy. The participants had nothing to disclose except Drs. Wesley, Espay and Lowenstein.Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as an Associate Editor of Movement Disorders, Frontiers in Movement Disorders and Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; receives royalties for publications of books from Lippincott, Williams & Wilkins and from Cambridge University Press; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics, Teva Pharmaceutical Industries Ltd., Impax Pharmaceuticals, Merz, Pfizer Inc, Solstice Neurosciences, LLC, Eli Lilly and Company, US WorldMeds; is a consultant for Chelsea Therapeutics, Solvay Pharmaceuticals, Inc. (now Abbvie); serves on the speakers' bureaus of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology, Movement Disorders Society; receives research support from CleveMed/Great Lakes Neurotechnologies, Michael J. Fox Foundation and the NIH.Dr. Lowenstein receives research support from the NIH.

1) Switching from natalizumab to fingolimod in patients with remitting-relapsing multiple sclerosis and 2) Topic of the month: Plenary sessions AAN Meeting April 2015. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mark Keegan interviews Dr. Ludwig Kappos about his paper on switching from natalizumab to fingolimod in patients with remitting-relapsing multiple sclerosis. Dr. Sarah Wesley is reading our e-Pearl of the week about dopamine-responsive dystonia. In the next part of the podcast Dr. Alberto Espay interviews Dr. Timothy Pedley about his Presidential Lecture at the AAN Meeting about the topics of neurologists' burnout, cost and quality of healthcare, value of neurology to congress and payers along with maintenance of certification. The participants had nothing to disclose except Drs. Keegan, Kappos, Wesley, Espay and Pedley.Dr. Keegan serves as Chief Editor of eMedicine; serves as an editorial board member of Multiple Sclerosis and Related Disorders; is a consultant for Novartis, Bristol-Meyers Squibb, Bionest Partners and receives research support from Terumo BCT and Caridian BCT.Dr. Kappos serves as an editorial board member of Multiple Sclerosis Journal, Multiple Sclerosis and Related Disorders and Journal of Neurology; receives research support from Actelion Pharmaceuticals Ltd, Addex, Bayer Schering Pharma, Biogen Idec, Biotica, CSL Behring, Genzyme Corporation, Eli Lilly and Company, Merck Serono, Mitsubishi, Novartis, Ono Pharma, Pfizer Inc, Receptos, Roche, Sanofi-aventis, Santhera, Siemens, Teva Pharmaceutical Industries Ltd., UCB, Xenoport, Swiss National Research Foundation and the European Union and The Swiss MS Society; honoraria and other payments for all these activities have been exclusively used for funding of research of his department.Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as an Associate Editor of Movement Disorders, Frontiers in Movement Disorders and Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; receives royalties for publications of books from Lippincott, Williams & Wilkins and from Cambridge University Press; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics, Teva Pharmaceutical Industries Ltd., Impax Pharmaceuticals, Merz, Pfizer Inc, Solstice Neurosciences, LLC, Eli Lilly and Company, US WorldMeds; is a consultant for Chelsea Therapeutics, Solvay Pharmaceuticals, Inc. (now Abbvie); serves on the speakers' bureaus of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology, Movement Disorders Society; receives research support from CleveMed/Great Lakes Neurotechnologies, Michael J. Fox Foundation and the NIH.Dr. Pedley serves as an editorial board member of Journal of Clinical Neurophysiology and Nature Reviews Neurology and as Editor-in-Chief (Neurology) for UpToDate; serves as President for the American Academy of Neurology; receives royalties form the publication of the books Current Practice of Clinical Electroencephalography, Epilepsy: A comprehensive Textbook and Merritt's Neurology.

1) Screening with MRI for accurate and rapid stroke treatment and 2) Topic of the month: Voices of encephalitis. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Kevin Barrett interviews Dr. Amie Hsia about her paper on screening with MRI for accurate and rapid stroke treatment. Dr. James Addington is reading our e-Pearl of the week about intracranial hypotension. In the next part of the podcast Dr. Lara Marcuse interviews Mia about the topic of Anti-N-methyl-D-aspartate. The participants had nothing to disclose except Dr. Loddenkemper and Addington.Dr. Barrett serves as an Associate Editor for Neurohospitalist; serves as an editorial board member of Neurology; and receives research support from the NIH.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section.

1) Time from convulsive status epilepticus onset to anticonvulsant administration in children and 2) Topic of the month: Voices of encephalitis. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. John Mytinger interviews Dr. Tobias Loddenkemper about his paper on time from convulsive status epilepticus onset to anticonvulsant administration in children. Dr. James Addington is reading our e-Pearl of the week about cannabis in epilepsy. In the next part of the podcast Dr. Lara Marcuse interviews Stephen Haslett about the topic of herpes simplex virus encephalitis. The participants had nothing to disclose except Dr. Loddenkemper and Addington.Dr. Loddenkemper performs video EEG long term monitoring, EEGs and other electrophysiological studies at Boston Children's Hospital (20% effort); evaluates pediatric neurology patients; serves on the Laboratory Accreditation Board for Long Term (Epilepsy and Intensive Care Unit) Monitoring, on the Council of the American Clinical Neurophysiology Society, on the American Board of Clinical Neurophysiology; serves as an Associate Editor for Seizure serves as Contributing Editor for Epilepsy Currents; serves as an Associate Editor for Wyllie's Treatment of Epilepsy 6th edition; is part of pending patent applications to detect seizures and to diagnose epilepsy; receives research support from the American Epilepsy Society, the Epilepsy Foundation of America, the Epilepsy Therapy Project, PCORI, the Pediatric Epilepsy Research Foundation, Cure, Danny-Did Foundation, HHV-6 Foundation, Lundbeck Inc., Eisai Inc., and Upsher-Smith Laboratories, Inc.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section.

1) Tele-stroke and tele-neurology and 2) Topic of the month: Voices of encephalitis. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Nina Solenski interviews Dr. Sunil Mutgi about his paper on tele-stroke and tele-neurology. Dr. James Addington is reading our e-Pearl of the week about cerebral vasospasm in subarachnoid hemorrhage. In the next part of the podcast Dr. Lara Marcuse interviews Kenneth Kearins and his wife Patricia Kennedy about the topic of autoimmune encephalitis with antibodies to LGI-1. The participants had nothing to disclose except Dr. Addington.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section.

Implementation of Genetic Testing. Lesson of the Week interviews from April 2015.

1) Rising cost of multiple sclerosis drugs in the U. S. and 2) Topic of the month: Immune-mediated necrotizing myopathy. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. David Jones interviews Dr. Daniel Hartung about his paper on the rising cost of multiple sclerosis drugs in the U. S. Dr. Adam Numis is reading our e-Pearl of the week about Walker-Warburg syndrome. In the next part of the podcast Dr. Ted Burns interviews Dr. Andy Mammen about the topic of treatment overview of immunotherapy for the immune-mediated myopathies. The participants had nothing to disclose except Drs. Jones, Hartung, Numis, Burns and Mammen.Dr. Jones has received personal compensation for attending consultant meetings for Biogen Idec, Novartis and Genzyme Corporation.Dr. Hartung serves on the data safety monitoring board for Kaiser Permanente Center for Health Research; is a consultant for Alkermes Inc.; receives research support from Alkermes Inc. and the Center for Disease Control and National Institute on Drug Abuse. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc.Dr. Mammen serves on the scientific advisory boards of aTYR Pharmaceuticals Inc. and Biogen Idec; serves as an editorial board member of Experimental Neurology and Arthritis and Rheumatism; receives license fee payments, royalties and revenue for a patent from INOVA Diagnostics Inc. for licensed test for anti-HMGCR antibodies; and research support from the NIH.